Population pharmacokinetics of domperidone in preterm neonates

Dailly, Éric; Drouineau, Marie-Hélène; Gournay, Véronique; Rozé, Jean‐Christophe; Jolliet, Pascale

doi:10.1007/s00228-008-0535-1

Cited by 7 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are some methods that have been published for the determination of domperidone in biological matrices. HPLC coupled with fluorescence detection (Dailly et al ., ; Michaud et al ., ) was reported in several studies, but those methods were time‐consuming and usually had low sensitivity. LC‐MS provided another possibility to determine domperidone in various matrices (Li et al ., ; Wu et al ., ).…”

Section: Introductionmentioning

confidence: 98%

Development and validation of UPLC‐MS/MS method for determination of domperidone in human plasma and its pharmacokinetic application

Wang

Qin

Jing

et al. 2012

Biomedical Chromatography

View full text Add to dashboard Cite

A sensitive, rapid and selective ultra-performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) method was developed for the determination and pharmacokinetic study of domperidone in human plasma. Diphenhydramine was used as the internal standard. Plasma sample pretreatment involved a one-step liquid-liquid extraction with a mixture of diethyl ether-dichloromethane (3:2, v/v). The analysis was carried out on an Acquity UPLC(TM) BEH C(18) column. The mobile phase consisted of methanol-water containing 10 mmol/L ammonium acetate and 0.5% (v/v) formic acid (60:40, v/v). The detection was performed on a triple quadrupole tandem mass spectrometer in multiple reaction monitoring mode via electrospray ionizationsource with positive mode. Each plasma sample was chromatographed within 2.1 min. The standard curves for domperidone were linear (r(2) ≥ 0.99) over the concentration range of 0.030-31.5 ng/mL with a lower limit of quantification of 0.030 ng/mL. The intra- and inter-day precision (relative standard deviation) values were not higher than 13% and accuracy (relative error) was from -7.6 to 1.2% at three quality control levels. The method herein described was superior to previous methods and was successfully applied to the pharmacokinetic study of domperidone in healthy Chinese volunteers after oral administration.

show abstract

Section: Introductionmentioning

confidence: 98%

Development and validation of UPLC‐MS/MS method for determination of domperidone in human plasma and its pharmacokinetic application

Wang

Qin

Jing

et al. 2012

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…In addition, the P450 system seems to be less developed in the preterm infant, and so the risk of toxicity is high. 9, 14 Dailly et al 15 showed that there is no clinically relevant change in domperidone elimination in preterm neonates. However, therapeutic concentrations can be different between adults and preterm neonates.…”

Section: Discussionmentioning

confidence: 99%

Effect of domperidone on the QTc interval in premature infants

et al. 2009

View full text Add to dashboard Cite

Objective:To evaluate the effect of domperidone use on corrected QT interval in premature infants.Study Design:A prospective study of premature infants receiving domperidone was included in this study. A baseline electrocardiogram was obtained just before and 3, 7 and 14 days after initiation of domperidone. Corrected QT was considered prolonged if it exceeded the upper limit for age.Result:A total of 40 premature infants were enrolled in this study. The mean birth weight of 1109±332 g, mean gestational age of 28.8±2.4 years and mean age at the onset of domperidone were 32.8±2 days. No difference in corrected QT interval was observed between just before and 3, 7 and 14 days after the start of the treatment. Two infants had corrected QT interval prolongation without any clinical side effect that resolved spontaneously.Conclusion:Our experience suggests that domperidone administered cautiously in modest doses does not result in arrhythmias or conduction defects in premature infants statistically. Additional data are needed to give optimal advice regarding the safety of domperidone treatment in premature infants.

show abstract

“…The silylated samples were then analyzed by GC/MS using selected ion monitoring (SIM) with linearity over the range 0.25-10 mgAEml )1 . Similarly, Dailly et al (15) have reported the use of LLE in a HPLC determination of domperidone in plasma in a pharmacokinetic study involving preterm neonates. In this method, 400 ll of plasma was used in the extraction and analysis involved reverse-phase HPLC and florescence detection resulting in a limit of quantification (LOQ) of 2 ngAEml )1 although the linear range was not detailed.…”

Section: Determination Of Drugs In Plasma/serummentioning

confidence: 98%

Microassay of drugs and modern measurement techniques

Millership

2011

Pediatric Anesthesia

View full text Add to dashboard Cite

Summary Details of the development of conventional analytical methods for the determination of drugs in pediatric plasma/serum samples via microassays are presented. Examples of the development of small‐volume sampling and the use of the newer detection systems such as LC/MS/MS for enhanced detection are presented. Dried blood spot sampling has conventionally been used for the study of inborn errors of metabolism using Guthrie cards. Limited applications in the area of drug‐level determination, for example, in therapeutic drug monitoring had been reported but the methodology had not been widely used up until relatively recently. In the last few years, there has been a resurgence of interest in this methodology for drug‐level determinations, and examples of drug analysis in pediatric and neonatal patients where the small‐volume samples are particularly useful are presented. The application of the methodology in pharmacokinetic/pharmacodynamic studies is discussed. The utilization of solid‐phase microextraction and stir bar sorptive extraction in drug analysis is presented. Clinical applications of these methodologies are reported including the development of in vivo solid‐phase microextraction.

show abstract

Population pharmacokinetics of domperidone in preterm neonates

Abstract: This pilot study designed with a limited sampling strategy showed that domperidone plasma concentrations were consistent with those reported in adults, suggesting that domperidone dosage regimen currently used in preterm neonates is suitable.

Cited by 7 publications

References 10 publications

Development and validation of UPLC‐MS/MS method for determination of domperidone in human plasma and its pharmacokinetic application

Development and validation of UPLC‐MS/MS method for determination of domperidone in human plasma and its pharmacokinetic application

Effect of domperidone on the QTc interval in premature infants

Microassay of drugs and modern measurement techniques

Contact Info

Product

Resources

About